Acentia Awarded 5-Year Contract from Rhode Island Department of Public Health

FALLS CHURCH, Va., Jan. 23, 2014 /PRNewswire-USNewswire/ -- Acentia, a premier provider of technology and management solutions, today announced it has been awarded a 5-year, $1.25 million contract from the State of Rhode Island Department of Health. The company will provide a secure cloud-based National Electronic Disease Surveillance System Base System (NBS) for the Department of Health's Division of Infectious Disease and Epidemiology (IDE).

IDE serves and protects the Rhode Island public by controlling the spread of infectious diseases and uses the NBS as the primary method of disease incidence monitoring, case management, disease surveillance, analysis, and notification of diseases to the Centers for Disease Control and Prevention (CDC). Under this new agreement, Acentia will move IDE's current RI-NBS to a secure cloud-based model.  Acentia will provide infrastructure and application administration for all RI-NBS users for the life of the agreement.

"We are honored that Acentia has been selected to support the Rhode Island Health Department's efforts to transform its legacy application from a traditional dedicated hardware configuration to a dynamic cloud environment," said Acentia EVP and Health Sector Executive Mike Raymond. "Moving the application to the cloud significantly reduces the cost while improving agility, scalability, and maintaining the highest level of security. Importantly, Acentia's support of the RI-NBS will allow the public health officers in Rhode Island to focus on their core business—keeping the population healthy."

About Acentia
Acentia is a premier employer and provider of technology and management solutions to public sector healthcare and Federal Government civilian customers. Our professionals build trusted partnerships with our customers by tackling their most difficult challenges on programs of national significance while consistently demonstrating value to our customers and the American taxpayer. For more information, visit www.acentia.com. Follow us on Twitter @Acentia.com.

SOURCE Acentia